A phase I dose escalation study of topical bexarotene in women at high risk for breast cancer

被引：0
|
作者：
Thomas, P. S.
Patel, A. B.
Contreras, A.
Liu, D. D.
Lee, J. J.
Khan, S.
Vornik, L. A.
Dimond, E. P.
Perloff, M.
Heckman-Stoddard, B. M.
Brown, P. H.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Northwestern Univ, Chicago, IL 60611 USA
[3] NCI, Bethesda, MD 20892 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-OT2-09-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-09-02
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer
    Erica L. Mayer
    M. E. Scheulen
    J. Beckman
    H. Richly
    A. Duarte
    M. M. Cotreau
    A. L. Strahs
    S. Agarwal
    L. Steelman
    E. P. Winer
    M. N. Dickler
    Breast Cancer Research and Treatment, 2013, 140 : 331 - 339
  • [22] A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer
    Mayer, Erica L.
    Scheulen, M. E.
    Beckman, J.
    Richly, H.
    Duarte, A.
    Cotreau, M. M.
    Strahs, A. L.
    Agarwal, S.
    Steelman, L.
    Winer, E. P.
    Dickler, M. N.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 140 (02) : 331 - 339
  • [23] A phase I, dose escalation study of lapatinib in combination with carboplatin, paclitaxel, with and without trastuzumab in patients with metastatic breast cancer
    Storniolo, A. M.
    Rubin, P.
    Magrinat, G.
    Parker, B.
    Rush-Tayler, A.
    Sheidler, V
    Aranjo, S.
    Shaw, C.
    Eldreth, N.
    Lott, G.
    Brechlin, J.
    Loftiss, J., I
    Fleming, R. A.
    Weber, B. L.
    CANCER RESEARCH, 2009, 69 (02) : 238S - 238S
  • [24] A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer
    Coombes, R. Charles
    Cardoso, Fatima
    Isambert, Nicolas
    Lesimple, Thierry
    Soulie, Patrick
    Peraire, Concepcion
    Fohanno, Veronique
    Kornowski, Anne
    Ali, Tauhid
    Schmid, Peter
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 140 (01) : 73 - 82
  • [25] A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer
    R. Charles Coombes
    Fatima Cardoso
    Nicolas Isambert
    Thierry Lesimple
    Patrick Soulié
    Concepcion Peraire
    Veronique Fohanno
    Anne Kornowski
    Tauhid Ali
    Peter Schmid
    Breast Cancer Research and Treatment, 2013, 140 : 73 - 82
  • [26] Dose Escalation Methods in Phase I Cancer Clinical Trials
    Le Tourneau, Christophe
    Lee, J. Jack
    Siu, Lillian L.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (10): : 708 - 720
  • [27] Conformal radiotherapy in pancreatic cancer: A phase I/II dose escalation study.
    Geh, JI
    Wells, P
    Williamson, RCN
    Dunn, P
    Dale, R
    Price, PM
    BRITISH JOURNAL OF CANCER, 1999, 80 : 62 - 62
  • [28] A Phase I Dose Escalation Study of Steroid Sulfatase Inhibitor BN83495/STX64 in Postmenopausal Women with ER Positive Breast Cancer
    Coombes, R. C.
    Schmid, P.
    Isambert, N.
    Soulie, P.
    Cardoso, F.
    Besse-Hammer, T.
    Lesimple, T.
    Slosman, D. O.
    Kornowski, A. H.
    Fohanno, V. M.
    Fumoleau, P.
    CANCER RESEARCH, 2009, 69 (24) : 739S - 739S
  • [29] A phase I study of docetaxel and bexarotene
    Wildi, Jonathan D.
    Baggstrom, Maria Q.
    Suresh, Rama
    Read, William
    Fracasso, Paula M.
    Govindan, Ramaswamy
    CHEMOTHERAPY, 2008, 54 (02) : 125 - 130
  • [30] Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer
    Bayet-Robert, Mathilde
    Kwiatkowski, Fabrice
    Leheurteur, Marianne
    Gachon, Francoise
    Planchat, Eloise
    Abrial, Catherine
    Mouret-Reynier, Marie-Ange
    Durando, Xavier
    Barthomeuf, Chantal
    Chollet, Philippe
    CANCER BIOLOGY & THERAPY, 2010, 9 (01) : 8 - 14
12345